BELLUS Health Inc. (TSE:BLU – Get Free Report) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$19.48 and traded as low as C$19.24. BELLUS Health shares last traded at C$19.48, with a volume of 28,666 shares changing hands.
BELLUS Health Price Performance
The company has a market capitalization of C$2.47 billion, a PE ratio of -20.29 and a beta of -0.28. The company has a quick ratio of 16.40, a current ratio of 33.42 and a debt-to-equity ratio of 0.32. The company’s fifty day simple moving average is C$19.48.
About BELLUS Health
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Featured Articles
- Five stocks we like better than BELLUS Health
- The 3 Best Retail Stocks to Shop for in August
- Analysts are Bullish on These 4 Oversold Large Cap Stocks
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 5 Tech Stocks to Buy Now, Ahead of the Q1 Reports
- When to Sell a Stock for Profit or Loss
- 5 Cheap Dividend Stocks: Which to Buy Now
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.
